With the advent of new technologies, several new pro-inflammatory cytokines have been characterized, such as IL-23, which plays an important role in the pathogenesis of a number of inflammatory diseases. IL-23 pathways, as well as other proteins involved in the pathogenesis of inflammatory diseases, are currently under development and show promising efficacy and safety in early patient trials with minimal safety risks. Preliminary studies show that IL-23 therapy of the second generation is effective in the main inflammatory mechanisms.